Protecting Patient Access to Cancer and Complex Therapies Act
About This Bill
Committee
Latest Action · July 7, 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
This bill modifies Medicare's payment system for certain drugs subject to price negotiations by requiring drug manufacturers to pay rebates to offset the difference between the standard payment rate and the negotiated price. Specifically, when a drug's negotiated price (called the "maximum fair price") is lower than the standard payment amount, manufacturers must pay a quarterly rebate equal to the savings multiplied by the number of units used. The rebate money goes into Medicare's trust fund. The bill also adjusts what patients pay in cost-sharing by basing it on the lower negotiated price rather than the standard rate, potentially reducing out-of-pocket costs for beneficiaries. The rebate requirements apply to "selected drugs"—those subject to Medicare's maximum fair price negotiation program—and take effect starting with the first quarter of the price negotiability period, with no specific end date mentioned.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.